Skip to main content

Table 1 Inclusion and Exclusion Criteria

From: A multi-centre, double-blind, 12-week, randomized, placebo-controlled trial to assess the efficacy of adjunctive N-Acetylcysteine for treatment-resistant PTSD: a study protocol

Inclusion criteria Exclusion criteria
Age ≥ 18 and able to provide written informed consent Already taking NAC, selenium or vitamin E
History of anaphylactic reaction to NAC
Current PTSD
Meets criteria for DSM-5 diagnosis of PTSD according to CAPS-5 monthly version
Known or suspected clinically unstable systemic medical disorder
History of epilepsy
Current asthma
Recent gastrointestinal ulcers
Treatment resistant PTSD defined as
(a) Minimum 1x trial of an antidepressant (SSRI or SNRI) for minimum 6 weeks without adequate response OR (b) completed a course of trauma-focused psychotherapy
Currently pregnant or breastfeeding
Planning to conceive a child during the trial or 3 months following
If currently taking an antidepressant medication
• Minimum of 6-weeks if recently initiated
• Dose must be stable for minimum 2 weeks
History of psychotic illness
  1. NAC N-acetyl cysteine, PTSD Posttraumatic Stress Disorder, DSM-5 Diagnostic & Statistical Manual of Mental Disorders Fifth edition, CAPS-5 Clinician-Administered PTSD Scale for DSM-5, SSRI Selective-serotonin reuptake inhibitor, SNRI Serotonin and norepinephrine reuptake inhibitor